Impact of Coronavirus Disease 2019 in a French Cohort of Myasthenia Gravis.
Guilhem SoleStéphane MathisDiane FriedmanEmmanuelle Salort-CampanaCéline TardFrançoise BouhourArmelle MagotDjillali AnnaneBernard ClairGwendal Le MassonAntoine SoulagesFanny DuvalLouis CarlaMarie-Hélène ViolleauTiphaine SaulnierSandrine Segovia-KuenyLéa KernJean-Christophe AntoineGuillemette BeaudonnetFrédérique AudicLaurent KremerJean-Baptiste ChansonAleksandra Nadaj-PaklezaKristl G ClaeysPascal CintasMarco SpinazziAlexandra Foubert-SamierShahram AttarianPublished in: Neurology (2021)
This registry-based cohort study shows that COVID-19 had a limited effect on most patients, and immunosuppressive medications and corticosteroids used for MG management are not risk factors for poorer outcomes. However, the risk of severe COVID-19 is elevated in patients with high MGFA classes (odds ratio, 102.6 [4.4-2,371.9]). These results are important for establishing evidence-based guidelines for the management of patients with MG during the COVID-19 pandemic.